NCT02747576

Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma

Completed Last updated 15 October 2021

What this trial tests

trial in Medulloblastoma in 137 participants. Completed in 31 August 2018.

Timeline

13 July 2016

Primary endpoint
25 June 2018

31 August 2018

Quick facts

Lead sponsor	St. Jude Children's Research Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	137
Start date	13 July 2016
Primary completion	25 June 2018
Estimated completion	31 August 2018
Sites	1 location across United States

Conditions studied

• Medulloblastoma — all drugs for Medulloblastoma →

Sponsor

St. Jude Children's Research Hospital

Who can join

Adults 12 to 30, any sex, with Medulloblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Survivors of pediatric medulloblastoma (MB) are at-risk for neurocognitive and social deficits, including specific skills such as facial affect recognition which is the ability to recognize the emotional expressions of another person. Because the underlying mechanisms of these deficits are poorly understood, the investigators propose to examine social-cognitive skills (i.e. facial affect recognition) and indices of brain integrity, including an established core neural network of face perception in MB survivors and healthy controls. By comparing these outcomes between survivors of MB and healthy controls, investigators seek to identify the areas of the brain that help individuals recognize emotions.

Primary Objective:

* To evaluate social cognition in adolescent and young adult survivors of pediatric medulloblastoma.

Secondary Objective:

* To examine indices of brain integrity and function and their association with facial affect recognition in survivors of pediatric medulloblastoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.